The US Patent and Trademark Office (USPTO) has granted two new patents including Patent No. 8,793,727 and 8,293,728 to Amarin's ultra pure omega-3 fatty acid product.
The patents include application No.12/702,889 and 13/349,153 for the use of Amarin's product, Vascepa (icosapent ethyl) capsules, as a treatment for hypertriglyceridemia.
Amarin chairman and chief executive officer Joseph Zakrzewski said the patent issuances represent another step forward in the company's effort to protect the commercial potential of Vascepa.
"Amarin's goal is to protect the commercial potential of Vascepa to beyond 2030 through patent protection, regulatory exclusivity and trade secrets and by taking advantage of manufacturing barriers to entry," Zakrzewski added.
In addition, the company is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the US.